Register Login

All Posts

Specimen Management in Fibrinolysis

I had the opportunity to become reacquainted with Jennifer Jacobsen, MLS (ASCP),Allina Health Laboratories, Minneapolis, while attending the Mayo Laboratories Coagulation Testing Quality conference in Rochester, Minnesota August 7–10. Jennifer has this question about specimen management on patients being treated with tissue plasminogen activator (TPA, Activase®, Alteplase®): George, both the prescribing information for Alteplase and Stago’s fibrinogen reagent package […]
read more

Monitoring Heparin with the Anti-Xa assay

From Crystal Azavedo: Hi George, Are you aware of any observation or randomized controlled trial data that compares bleeding and thrombosis risk in patients receiving unfractionated heparin monitored with the activated partial thromboplastin time (aPTT, PTT) compared to monitoring with anti-Xa? In other words, are there clinical outcome data that suggest monitoring with anti-Xa improves patient outcomes? Thanks!! […]
read more